Health Condition 1: B459- Cryptococcosis, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: NIL: NIL
Sponsors
Fungal Infection Study Forum
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patient with age more than 18 years with first episode of CM and or CC 2. Diagnosis of CM arrived by CSF Cryptococcal Antigen (CrAg) Positive or Positive Cryptococcal culture, India Ink, Cryptococcal PCR 3. Blood culture positive for cryptococcus 4. BAL culture positive for cryptococcus, or BAL CrAg titer more than 1: 8, 5. Serous cavity (ascites, pleural or pericardial) fluids CrAg, culture, PCR positive 6. Tissue biopsy showing characteristics yeast cells and/or serum or BAL CrAg positive.
Exclusion criteria
Exclusion criteria: 1. Not willing to participate or refuse consent. 2. HIV infected patients 3. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical characteristics, risk factors and outcome of non HIV CM and CC Duration of anti fungal treatment and outcomeTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To study cryptococcal species & its drug susceptibility in non-HIV associated CM Difference in clinical presentation & outcome of C. gatii versus C. Neoformans Treatment & outcome of patients with CC Species distributions & Drug susceptibility pattern & outcome at 8 & 12 weeks Incidence of PR following antifungal treatment for CM Reduction in the immunosuppression (overall, specific agent) & PR Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDr Atul K Patel
Sterling Hospitals
Outcome results
None listed